Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.

Background: In placebo-controlled trials, reslizumab, an anti-IL-5 monoclonal antibody, significantly reduced asthma exacerbations and improved lung function and asthma control in patients with eosinophilic asthma.

Objective: This open-label extension study evaluated safety and efficacy of reslizumab for up to 24 months.

Methods: After participation in 1 of 3 placebo-controlled, phase III trials in moderate-to-severe eosinophilic asthma, patients received reslizumab 3.

Acute Rejection of a Kidney Transplant in a Patient With Common Variable Immunodeficiency: A Case Report.

Common variable immunodeficiency is a primary immunodeficiency characterized by hypogammaglobulinemia and recurrent bacterial infections. We report a case of a 44-year-old male patient with end-stage renal disease and an established diagnosis of common variable immunodeficiency who underwent a living unrelated kidney transplant. He remained nearly infection free on maintenance immunoglobulin replacement.